Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways / edited by Yosef Yarden, Moshe Elkabets.
Contributor(s): SpringerLink (Online service)
| Yarden, Yosef., editor literario | Elkabets, Moshe., editor literario
Series: (Resistance to Targeted Anti-Cancer Therapeutics, 2196-5501; 15); (Biomedical and Life Sciences (Springer-11642)).Publisher: Cham, Switzerland : Springer International Publishing, 2018Description: 1 recurso en línea (XX, 242 páginas 22 ilustraciones a color).ISBN: 9783319679327.Subject: Células cancerosas | AntineoplásicosOnline resources: Acceso a este recurso digital (usuarios Universidad Europea de Madrid)
| Item type | Current library | Collection | Call number | Status | Date due | Barcode | Item holds | |
|---|---|---|---|---|---|---|---|---|
LIBRO-E NO PRÉSTAMO
|
Madrid Digital Acceso Electrónico (UEM) | Ciencias de la Salud | RC271.C5 2018 EB (Browse shelf(Opens below)) | Acceso electrónico | eBook.12022220 |
Browsing Madrid Digital shelves, Shelving location: Acceso Electrónico (UEM) Close shelf browser (Hides shelf browser)
| RC271.C5 2015 EB Emerging Trends in Immunomodulatory Nanomaterials Toward Cancer Therapy | RC271 .C5 2016 EB Cancer Drug Resistance : Overviews and Methods | RC271 .C5 2018 EB Mechanisms of Drug Resistance in Cancer Therapy | RC271.C5 2018 EB Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways | RC271.C5 2020 EB Drug Targets in Cellular Processes of Cancer : From Nonclinical to Preclinical Models | RC271.C5 2020 EB Phase I Oncology Drug Development | RC271.C5 2021 EB Polyphenols-based Nanotherapeutics for Cancer Management |
Resistance of colorectal tumors to anti-EGFR antibodies -- Resistance of lung cancer to kinase inhibitors specific to EGFR or ALK -- Mechanisms of action and resistance of trastuzumab in breast cancer -- Mechanisms of resistance to molecular therapies targeting the HGF/MET axis -- RAF, MEK and ERK inhibitors as anti-cancer drugs: intrinsic and acquired resistance as a major therapeutic challenge -- Mechanisms of resistance to PI3K and AKT inhibitors -- Sensitivity and resistance to BH3 mimetics in cancer therapy -- Resistance mechanisms to cyclin-dependent kinase inhibitors -- Resistance to inhibitors of angiogenesis.
This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance.
There are no comments on this title.